IRIS Accounts Production v26.1.10.61 08147391 director 1.10.24 30.9.25 30.9.25 Medium entities the processing and sale of gelatine, vegetarian gelling agents and other food ingredients. true false true true false false false true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh081473912024-09-30081473912025-09-30081473912024-10-012025-09-30081473912023-09-30081473912023-10-012024-09-30081473912024-09-3008147391ns15:EnglandWales2024-10-012025-09-3008147391ns14:PoundSterling2024-10-012025-09-3008147391ns10:Director12024-10-012025-09-3008147391ns10:PrivateLimitedCompanyLtd2024-10-012025-09-3008147391ns10:MediumEntities2024-10-012025-09-3008147391ns10:Audited2024-10-012025-09-3008147391ns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-10-012025-09-3008147391ns10:Medium-sizedCompaniesRegimeForAccounts2024-10-012025-09-3008147391ns10:FullAccounts2024-10-012025-09-300814739112024-10-012025-09-3008147391ns10:RegisteredOffice2024-10-012025-09-3008147391ns5:CurrentFinancialInstruments2025-09-3008147391ns5:CurrentFinancialInstruments2024-09-3008147391ns5:Non-currentFinancialInstruments2025-09-3008147391ns5:Non-currentFinancialInstruments2024-09-3008147391ns5:ShareCapital2025-09-3008147391ns5:ShareCapital2024-09-3008147391ns5:RetainedEarningsAccumulatedLosses2025-09-3008147391ns5:RetainedEarningsAccumulatedLosses2024-09-3008147391ns5:ShareCapital2023-09-3008147391ns5:RetainedEarningsAccumulatedLosses2023-09-3008147391ns5:RetainedEarningsAccumulatedLosses2023-10-012024-09-3008147391ns5:RetainedEarningsAccumulatedLosses2024-10-012025-09-3008147391ns5:NetGoodwill2024-10-012025-09-3008147391ns5:IntangibleAssetsOtherThanGoodwill2024-10-012025-09-3008147391ns5:OwnedAssets2024-10-012025-09-3008147391ns5:OwnedAssets2023-10-012024-09-3008147391132024-10-012025-09-3008147391132023-10-012024-09-300814739142024-10-012025-09-300814739142023-10-012024-09-300814739152024-10-012025-09-300814739152023-10-012024-09-3008147391ns5:NetGoodwill2024-09-3008147391ns5:NetGoodwill2025-09-3008147391ns5:NetGoodwill2024-09-3008147391ns5:LandBuildings2024-09-3008147391ns5:PlantMachinery2024-09-3008147391ns5:FurnitureFittings2024-09-3008147391ns5:MotorVehicles2024-09-3008147391ns5:LandBuildings2024-10-012025-09-3008147391ns5:PlantMachinery2024-10-012025-09-3008147391ns5:FurnitureFittings2024-10-012025-09-3008147391ns5:MotorVehicles2024-10-012025-09-3008147391ns5:LandBuildings2025-09-3008147391ns5:PlantMachinery2025-09-3008147391ns5:FurnitureFittings2025-09-3008147391ns5:MotorVehicles2025-09-3008147391ns5:LandBuildings2024-09-3008147391ns5:PlantMachinery2024-09-3008147391ns5:FurnitureFittings2024-09-3008147391ns5:MotorVehicles2024-09-3008147391ns5:WithinOneYearns5:CurrentFinancialInstruments2025-09-3008147391ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-3008147391ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2025-09-3008147391ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2024-09-3008147391ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2025-09-3008147391ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-09-3008147391ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2025-09-3008147391ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2024-09-3008147391ns5:HirePurchaseContractsns5:BetweenOneFiveYears2025-09-3008147391ns5:HirePurchaseContractsns5:BetweenOneFiveYears2024-09-3008147391ns5:HirePurchaseContracts2025-09-3008147391ns5:HirePurchaseContracts2024-09-3008147391ns5:Secured2025-09-3008147391ns5:Secured2024-09-3008147391ns5:AcceleratedTaxDepreciationDeferredTax2025-09-3008147391ns5:AcceleratedTaxDepreciationDeferredTax2024-09-3008147391ns5:DeferredTaxation2024-09-3008147391ns5:DeferredTaxation2024-10-012025-09-3008147391ns5:DeferredTaxation2025-09-3008147391ns5:RetainedEarningsAccumulatedLosses2024-09-3008147391ns10:Director112024-09-3008147391ns10:Director112023-09-3008147391ns10:Director112024-10-012025-09-3008147391ns10:Director112023-10-012024-09-3008147391ns10:Director112025-09-3008147391ns10:Director112024-09-30
REGISTERED NUMBER: 08147391 (England and Wales)






















Healan Ingredients Limited

Strategic Report, Report of the Director and

Financial Statements for the Year Ended 30 September 2025






Healan Ingredients Limited (Registered number: 08147391)






Contents of the Financial Statements
for the year ended 30 September 2025




Page

Company Information 1

Strategic Report 2

Report of the Director 3

Report of the Independent Auditors 4

Statement of Comprehensive Income 7

Balance Sheet 8

Statement of Changes in Equity 9

Cash Flow Statement 10

Notes to the Cash Flow Statement 11

Notes to the Financial Statements 12


Healan Ingredients Limited

Company Information
for the year ended 30 September 2025







DIRECTOR: M Lapi





REGISTERED OFFICE: Sands Top
North Newbald
York
YO43 4SW





REGISTERED NUMBER: 08147391 (England and Wales)





AUDITORS: Smailes Goldie
Chartered Accountants
Statutory Auditor
Regent's Court
Princess Street
Hull
East Yorkshire
HU2 8BA

Healan Ingredients Limited (Registered number: 08147391)

Strategic Report
for the year ended 30 September 2025

The director presents his strategic report for the year ended 30 September 2025.

PRINCIPAL ACTIVITY
The principal activities of the company in the year under review were that of the processing and sale of gelatine and vegetarian gelling agents.

REVIEW OF BUSINESS
During the year, the company delivered a satisfactory performance and generated a healthy profit, notwithstanding a reduction in sales revenue. Margins remained under pressure in a competitive trading environment, while operating costs continued to be elevated. Interest payable reduced during the year, reflecting lower interest rates and the ongoing repayment of borrowings.

We would like to place on record our appreciation of the company's dedicated workforce. Their commitment and professionalism throughout the year were instrumental in ensuring continued service to our customers, the retention of our Halal Accreditation and the maintenance of our AA grade rating for BRCGS.

PRINCIPAL RISKS AND UNCERTAINTIES
The principal risks facing the company remain those associated with fluctuations in raw material prices and currency volatility. Although inflation is expected to stabilise, the cost increases already experienced are likely to remain, and operating costs are not expected to reduce materiality in the near term. The company's ability to recover such increases from its principal customers, many of whom operate in price-sensitive sectors and require long-term price certainty, remains uncertain, particularly in the context of a slowing economy. The company will continue to work closely with both customers and suppliers in managing these risks.

The key uncertainties identified are:
- Unexpected fluctuations in demand and product availability.
- Potential price volatility.
- Disruption to the workforce and changes in working practices.
- Exchange rate volatility.

The company believes that, through the measures adopted, including maintaining an international supplier base and holding substantial stock levels in its UK warehouse, it has put in place a robust framework to mitigate downside risk.

KEY PERFORMANCE INDICATORS
The director monitors performance through regular review of volumes, turnover, gross and net margins and cash headroom. With the exception of volumes, these measures are reflected in the financial statements.

FUTURE DEVELOPMENTS OUR COMMITMENT TO RESEARCH AND DEVELOPMENT
The company will continue its focus on ensuring the safety and quality of its products, while also seeking to expand its range and capacity through investment in new production lines over the coming year. It will further develop its systems to enhance product safety, quality, and traceability, and will continue to invest in order to maintain its AA grade accreditation under the BRC Global Standard for Food Safety. In order to achieve these objectives, the company will continue to rely on the support of its staff and remains committed to their ongoing development.

ON BEHALF OF THE BOARD:





M Lapi - Director


2 June 2026

Healan Ingredients Limited (Registered number: 08147391)

Report of the Director
for the year ended 30 September 2025

The director presents his report with the financial statements of the company for the year ended 30 September 2025.

DIVIDENDS
Interim dividends of £682,594 (2024 £449,950) were paid during the year. No final dividend will be distributed.

DIRECTOR
M Lapi held office during the whole of the period from 1 October 2024 to the date of this report.

DISCLOSURE IN THE STRATEGIC REPORT
In accordance with s414(C) (11) of the Companies Act, included in the Strategic Report is information relating to the events occurring in the period and future developments which would otherwise be required by Schedule 7 of the 'large and medium sized companies and groups (accounts and reports) regulation 2008' to be contained in a Director's Report. I also include information on the financial risk management policies within the Strategic Report.

STATEMENT OF DIRECTOR'S RESPONSIBILITIES
The director is responsible for preparing the Strategic Report, the Report of the Director and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the director is aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS
The auditors, Smailes Goldie, will be deemed to be re-appointed under s487 of the Companies Act 2006.

ON BEHALF OF THE BOARD:





M Lapi - Director


2 June 2026

Report of the Independent Auditors to the Members of
Healan Ingredients Limited

Opinion
We have audited the financial statements of Healan Ingredients Limited (the 'company') for the year ended 30 September 2025 which comprise the Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 30 September 2025 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.

Other information
The director is responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Director, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Director for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Director have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Director.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of director's remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Report of the Independent Auditors to the Members of
Healan Ingredients Limited


Responsibilities of director
As explained more fully in the Statement of Director's Responsibilities set out on page three, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the director is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities,
including fraud and non-compliance with laws and regulations, was focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, the Food Safety Act 1990 and applicable food standards, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation. An understanding of these laws and regulations and the extent of compliance was obtained through discussion with management and inspecting legal and regulatory correspondence.

We assessed the susceptibility of the company's financial statements to material misstatement, including
obtaining an understanding of how fraud might occur, by making enquiries of management and considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were
indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed
procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with HMRC, relevant regulators and the company's legal advisors.

Due to the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including
those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of
non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves
intentional concealment, forgery, collusion, omission, or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Healan Ingredients Limited


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Stephen Bramall BSc FCA (Senior Statutory Auditor)
for and on behalf of Smailes Goldie
Chartered Accountants
Statutory Auditor
Regent's Court
Princess Street
Hull
East Yorkshire
HU2 8BA

2 June 2026

Healan Ingredients Limited (Registered number: 08147391)

Statement of Comprehensive Income
for the year ended 30 September 2025

2025 2024
Notes £    £   

TURNOVER 10,633,201 14,156,683

Cost of sales 9,762,544 12,858,051
GROSS PROFIT 870,657 1,298,632

Administrative expenses 440,034 483,590
430,623 815,042

Other operating income - 20,000
OPERATING PROFIT 5 430,623 835,042

Interest receivable and similar income 6,047 -
436,670 835,042

Interest payable and similar expenses 6 56,244 94,405
PROFIT BEFORE TAXATION 380,426 740,637

Tax on profit 7 104,299 185,174
PROFIT FOR THE FINANCIAL YEAR 276,127 555,463

OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME FOR
THE YEAR

276,127

555,463

Healan Ingredients Limited (Registered number: 08147391)

Balance Sheet
30 September 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 9 - -
Tangible assets 10 1,657,969 1,737,352
1,657,969 1,737,352

CURRENT ASSETS
Stocks 11 3,882,789 3,076,119
Debtors 12 2,283,075 2,181,756
Cash at bank 452,865 1,108,379
6,618,729 6,366,254
CREDITORS
Amounts falling due within one year 13 2,891,618 2,222,728
NET CURRENT ASSETS 3,727,111 4,143,526
TOTAL ASSETS LESS CURRENT
LIABILITIES

5,385,080

5,880,878

CREDITORS
Amounts falling due after more than one
year

14

(633,362

)

(716,735

)

PROVISIONS FOR LIABILITIES 18 (134,882 ) (140,840 )
NET ASSETS 4,616,836 5,023,303

CAPITAL AND RESERVES
Called up share capital 19 355,555 355,555
Retained earnings 20 4,261,281 4,667,748
SHAREHOLDERS' FUNDS 4,616,836 5,023,303

The financial statements were approved by the director and authorised for issue on 2 June 2026 and were signed by:





M Lapi - Director


Healan Ingredients Limited (Registered number: 08147391)

Statement of Changes in Equity
for the year ended 30 September 2025

Called up
share Retained Total
capital earnings equity
£    £    £   
Balance at 1 October 2023 355,555 4,562,235 4,917,790

Changes in equity
Dividends - (449,950 ) (449,950 )
Total comprehensive income - 555,463 555,463
Balance at 30 September 2024 355,555 4,667,748 5,023,303

Changes in equity
Dividends - (682,594 ) (682,594 )
Total comprehensive income - 276,127 276,127
Balance at 30 September 2025 355,555 4,261,281 4,616,836

Healan Ingredients Limited (Registered number: 08147391)

Cash Flow Statement
for the year ended 30 September 2025

2025 2024
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 336,413 3,904,585
Interest paid (56,244 ) (94,405 )
Tax paid (185,925 ) (297,324 )
Net cash from operating activities 94,244 3,512,856

Cash flows from investing activities
Purchase of tangible fixed assets (29,127 ) (85,821 )
Interest received 6,047 -
Net cash from investing activities (23,080 ) (85,821 )

Cash flows from financing activities
Loan repayments in year (33,579 ) (205,434 )
Movement in other credit facilities - (1,797,103 )
Capital repayments in year (6,441 ) (5,861 )
Net amount repaid/withdrawn by director (4,064 ) 11,181
Equity dividends paid (682,594 ) (449,950 )
Net cash from financing activities (726,678 ) (2,447,167 )

(Decrease)/increase in cash and cash equivalents (655,514 ) 979,868
Cash and cash equivalents at beginning
of year

2

1,108,379

128,511

Cash and cash equivalents at end of year 2 452,865 1,108,379

Healan Ingredients Limited (Registered number: 08147391)

Notes to the Cash Flow Statement
for the year ended 30 September 2025

1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

2025 2024
£    £   
Profit before taxation 380,426 740,637
Depreciation charges 108,510 98,752
Loss on disposal of fixed assets - 19
Finance costs 56,244 94,405
Finance income (6,047 ) -
539,133 933,813
(Increase)/decrease in stocks (806,670 ) 2,616,911
(Increase)/decrease in trade and other debtors (101,319 ) 1,383,620
Increase/(decrease) in trade and other creditors 705,269 (1,029,759 )
Cash generated from operations 336,413 3,904,585

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 30 September 2025
30.9.25 1.10.24
£    £   
Cash and cash equivalents 452,865 1,108,379
Year ended 30 September 2024
30.9.24 1.10.23
£    £   
Cash and cash equivalents 1,108,379 128,511


3. ANALYSIS OF CHANGES IN NET FUNDS/(DEBT)

At 1.10.24 Cash flow At 30.9.25
£    £    £   
Net cash
Cash at bank 1,108,379 (655,514 ) 452,865
1,108,379 (655,514 ) 452,865
Debt
Finance leases (47,199 ) 6,441 (40,758 )
Debts falling due within 1 year (29,636 ) (9,036 ) (38,672 )
Debts falling due after 1 year (675,977 ) 42,615 (633,362 )
(752,812 ) 40,020 (712,792 )
Total 355,567 (615,494 ) (259,927 )

Healan Ingredients Limited (Registered number: 08147391)

Notes to the Financial Statements
for the year ended 30 September 2025

1. STATUTORY INFORMATION

Healan Ingredients Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The director, having considered the available information, has a reasonable expectation that the company has adequate resources to continue in operational existence for a period of 12 months from the date of approval of these financial statements and therefore has prepared the financial statements on a going concern basis.

Turnover
Turnover is measured at the fair value of the consideration received or receivable net of VAT and trade discounts. The policies adopted for the recognition of turnover are as follows:

Turnover from the sale of goods is recognised when significant risks and rewards of ownership of the goods have transferred to the buyer, the amount of turnover can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transaction can be measured reliably. This is usually on dispatch of the goods.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2013, has been amortised evenly over its estimated useful life of five years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Freehold property - 2% on cost
Plant and machinery - 10% - 20% straight line
Fixtures and fittings - 10% - 20% straight line
Motor vehicles - 33% on cost

Tangible fixed assets are stated at cost less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended.

Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing stock to its present location and condition. Cost is calculated using the first-in, first-out formula. Provision is made for damaged, obsolete and slow-moving stock where appropriate.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Comprehensive Income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Healan Ingredients Limited (Registered number: 08147391)

Notes to the Financial Statements - continued
for the year ended 30 September 2025

2. ACCOUNTING POLICIES - continued
Tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Employee benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Debtors and creditors receivable/payable within one year
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.

Loans and borrowings
Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.

3. EMPLOYEES AND DIRECTORS
2025 2024
£    £   
Wages and salaries 688,164 762,406
Social security costs 71,783 66,957
Other pension costs 54,560 54,467
814,507 883,830

The average number of employees during the year was as follows:
2025 2024

Production 12 13
Quality control 5 6
Sales and logistics 6 5
Management and administration 5 6
28 30

4. DIRECTORS' EMOLUMENTS
2025 2024
£    £   
Director's remuneration - 7,580

Healan Ingredients Limited (Registered number: 08147391)

Notes to the Financial Statements - continued
for the year ended 30 September 2025

5. OPERATING PROFIT

The operating profit is stated after charging:

2025 2024
£    £   
Depreciation - owned assets 108,510 98,752
Loss on disposal of fixed assets - 19
Auditors' remuneration - for audit services 10,850 10,075

6. INTEREST PAYABLE AND SIMILAR EXPENSES
2025 2024
£    £   
Bank interest 4,198 4,800
Bank loan interest - 665
Mortgage interest 51,476 59,158
Loan interest - 1,534
Other interest 570 28,248
56,244 94,405

7. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2025 2024
£    £   
Current tax:
UK corporation tax 110,258 185,926
Prior year over provision - (163 )
Total current tax 110,258 185,763

Deferred tax:
Deferred tax:
Origination and reversal of
timing differences (10,871 ) (589 )
Prior year under provision 4,912 -
Total deferred tax (5,959 ) (589 )

Tax on profit 104,299 185,174

Healan Ingredients Limited (Registered number: 08147391)

Notes to the Financial Statements - continued
for the year ended 30 September 2025

7. TAXATION - continued

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

2025 2024
£    £   
Profit before tax 380,426 740,637
Profit multiplied by the standard rate of corporation tax in the UK of 25%
(2024 - 25%)

95,107

185,159

Effects of:
Expenses not deductible for tax purposes 696 1,431
Income not taxable for tax purposes - (5,000 )
Depreciation on non qualifying assets 3,585 3,747


Prior year under/(over) provision 4,911 (163 )
Total tax charge 104,299 185,174

UK corporation tax has been charged at 25% (2024 25%).

The expected net reversal of deferred tax liabilities in the next financial year is £3,232. This is due to the reversal of accelerated capital allowances.

8. DIVIDENDS
2025 2024
£    £   
Ordinary A shares of £1 each
Interim 605,052 398,103
Ordinary B shares of £1 each
Interim 77,542 51,847
682,594 449,950

9. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 October 2024
and 30 September 2025 325,870
AMORTISATION
At 1 October 2024
and 30 September 2025 325,870
NET BOOK VALUE
At 30 September 2025 -
At 30 September 2024 -

Healan Ingredients Limited (Registered number: 08147391)

Notes to the Financial Statements - continued
for the year ended 30 September 2025

10. TANGIBLE FIXED ASSETS
Fixtures
Freehold Plant and and Motor
property machinery fittings vehicles Totals
£    £    £    £    £   
COST
At 1 October 2024 1,473,588 839,988 84,053 61,490 2,459,119
Additions - 16,320 12,807 - 29,127
At 30 September 2025 1,473,588 856,308 96,860 61,490 2,488,246
DEPRECIATION
At 1 October 2024 139,315 500,953 69,361 12,138 721,767
Charge for year 24,072 69,662 6,208 8,568 108,510
At 30 September 2025 163,387 570,615 75,569 20,706 830,277
NET BOOK VALUE
At 30 September 2025 1,310,201 285,693 21,291 40,784 1,657,969
At 30 September 2024 1,334,273 339,035 14,692 49,352 1,737,352

Included in cost of land and buildings is freehold land of £ 270,000 (2024 - £ 270,000 ) which is not depreciated.

11. STOCKS
2025 2024
£    £   
Raw materials 3,882,789 3,076,119

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 2,234,523 2,111,516
Other debtors - 20,000
Prepayments 48,552 50,240
2,283,075 2,181,756

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Bank loans and overdrafts (see note 15) 38,672 29,636
Hire purchase contracts (see note 16) 40,758 6,441
Trade creditors 2,418,796 1,743,738
Corporation tax 110,258 185,926
Social security and other taxes 77,171 59,112
Other creditors 8,556 8,884
Directors' current accounts 2,273 6,337
Accrued expenses 195,134 182,654
2,891,618 2,222,728

14. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2025 2024
£    £   
Bank loans (see note 15) 633,362 675,977
Hire purchase contracts (see note 16) - 40,758
633,362 716,735

Healan Ingredients Limited (Registered number: 08147391)

Notes to the Financial Statements - continued
for the year ended 30 September 2025

15. LOANS

An analysis of the maturity of loans is given below:

2025 2024
£    £   
Amounts falling due within one year or on demand:
Bank loans 38,672 29,636

Amounts falling due between one and two years:
Bank loans 41,379 32,007

Amounts falling due between two and five years:
Bank loans 142,340 112,219

Amounts falling due in more than five years:

Repayable by instalments
Bank loans 449,643 531,751

16. LEASING AGREEMENTS

Minimum lease payments under hire purchase fall due as follows:

2025 2024
£    £   
Net obligations repayable:
Within one year 40,758 6,441
Between one and five years - 40,758
40,758 47,199

17. SECURED DEBTS

The following secured debts are included within creditors:

2025 2024
£    £   
Bank loans 672,034 705,613
Hire purchase contracts 40,758 47,199
712,792 752,812

The bank loans and other creditors are secured via a fixed charge over the land and buildings, a floating charge over the remaining assets, and a debenture granted in favour of the bank.

The director has also given a personal guarantee of £12,500.

18. PROVISIONS FOR LIABILITIES
2025 2024
£    £   
Deferred tax
Accelerated capital allowances 135,156 142,075
Other timing differences (274 ) (1,235 )
134,882 140,840

Healan Ingredients Limited (Registered number: 08147391)

Notes to the Financial Statements - continued
for the year ended 30 September 2025

18. PROVISIONS FOR LIABILITIES - continued

Deferred
tax
£   
Balance at 1 October 2024 140,840
Credit to Statement of Comprehensive Income during year (5,958 )
Balance at 30 September 2025 134,882

19. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £ £

320,000 Ordinary A £1 320,000 320,000
35,555 Ordinary B £1 35,555 35,555
355,555 355,555

The Ordinary A and Ordinary B shares rank pari passu in all material respects save as for dividends. The directors may at any time resolve to declare a dividend on one or both of the respective classes of shares or to declare a dividend on each of them at different rates.

20. RESERVES
Retained
earnings
£   

At 1 October 2024 4,667,748
Profit for the year 276,127
Dividends (682,594 )
At 30 September 2025 4,261,281

The retained earnings reserve represents cumulative profits and losses net of dividends and other adjustments.

21. PENSION COMMITMENTS

The company operates a money purchase pension scheme for its employees. The assets of the schemes are held separately from those of the company in independently administered funds. The pension cost charge represents contributions of £54,560 (2024 £54,467) payable to the pension scheme during the year. The amounts payable at the year end were £3,045 (2024 £8,843).

22. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 30 September 2025 and 30 September 2024:

2025 2024
£    £   
M Lapi
Balance outstanding at start of year - 4,844
Amounts advanced - 11,080
Amounts repaid - (15,924 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year - -

Healan Ingredients Limited (Registered number: 08147391)

Notes to the Financial Statements - continued
for the year ended 30 September 2025

23. RELATED PARTY DISCLOSURES

During the year, total dividends of £276,691 (2024 £238,862) were paid to the director and his close family members.

During the year, sales of £115,166 and purchases of £24,973 were transacted with a company owned by a close relative of the director. At the year end, the related party owed the company £Nil (2024 £52,361).

During the year total dividends of £328,361 (2024 £159,241) were paid to a shareholder holding significant influence.